NASDAQ:TRML
Tourmaline Bio, Inc. Stock News
$14.21
-0.490 (-3.33%)
At Close: Jun 25, 2024
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
07:10am, Thursday, 23'rd May 2024
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve th
– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
07:00am, Monday, 13'th May 2024
– Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Dise
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
07:00am, Tuesday, 19'th Mar 2024
– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial
Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going
09:51am, Friday, 15'th Mar 2024
Tourmaline Bio, Inc. (TRML) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Tourmaline Bio to Present at Upcoming Investor Conferences
07:30am, Tuesday, 27'th Feb 2024
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve t
What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'
09:51am, Thursday, 08'th Feb 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Tourmaline Bio, Inc. (TRML) could be a great choice. It is one of the several stocks that passed through our "R
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
08:00am, Thursday, 01'st Feb 2024
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve t
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically impr
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
07:00am, Thursday, 25'th Jan 2024
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically impr
Tourmaline Bio Announces Proposed Public Offering of Common Stock
04:05pm, Wednesday, 24'th Jan 2024
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically impr
Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026
Tourmaline Bio added to the NASDAQ Biotechnology Index
04:00pm, Friday, 15'th Dec 2023
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically impr
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
07:30am, Thursday, 14'th Dec 2023
NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically impr
Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6
02:09pm, Wednesday, 01'st Nov 2023
Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye disease and atherosclerotic cardiovascular disease. The ongoing phase 2b spiriTED study, which is usi